Effects of palmitoylethanolamide and luteolin in an animal model of anxiety/depression

Rosalia Crupi, Irene Paterniti, Akbar Ahmad, Michela Campolo, Emanuela Esposito, Salvatore Cuzzocrea

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

The antidepressant effect of a compound formed by co-ultramicronized palmitoylethanolamide (PEA) and luteolin (PEA+luteolin) was investigated in a mouse model of anxiety/depressive-like behavior. 129Sv/Ev mice were subjected to 6 weeks of corticosterone administration, and then behavior, neurogenesis, neuroplasticity, neurotrophic and apoptotic proteins expression were evaluated. The effect of PEA+luteolin compound treatment (1mg/kg, i.p.), on depression-like behaviour was assessed using different paradigms such as open field, novelty suppressed feeding, forced swim test and elevated plus maze. In particular in the open field, novelty suppressed feeding and elevated plus maze the time spent in the open arm was employed as an indicator of anxiety; forced swim test was used to evaluate the antidepressant capacity of PEA+luteolin on immobility time as an indicator of depression. Adult hippocampal neurogenesis and neuroplasticity were evaluated by immunohistochemical techniques; brain-derived neurotrophic factor and apoptotic protein (Bax and Bcl2) expression were studied by immunostaining and Western blot analysis. For the first time we demonstrated that PEA+luteolin compound exerts a significant antidepressant effect a low dose and may be considered as a novel therapeutic strategy in depression.

Original languageEnglish (US)
Pages (from-to)989-1001
Number of pages13
JournalCNS and Neurological Disorders - Drug Targets
Volume12
Issue number7
DOIs
StatePublished - Nov 2013
Externally publishedYes

Fingerprint

Luteolin
Anxiety
Animal Models
Depression
Antidepressive Agents
Neuronal Plasticity
Neurogenesis
bcl-2-Associated X Protein
Brain-Derived Neurotrophic Factor
Nerve Growth Factors
Corticosterone
Western Blotting
palmidrol

Keywords

  • Antidepressant
  • Behavior
  • Depression
  • Inflammation
  • Mice
  • Neurogenesis

ASJC Scopus subject areas

  • Neuroscience(all)
  • Pharmacology

Cite this

Effects of palmitoylethanolamide and luteolin in an animal model of anxiety/depression. / Crupi, Rosalia; Paterniti, Irene; Ahmad, Akbar; Campolo, Michela; Esposito, Emanuela; Cuzzocrea, Salvatore.

In: CNS and Neurological Disorders - Drug Targets, Vol. 12, No. 7, 11.2013, p. 989-1001.

Research output: Contribution to journalArticle

Crupi, Rosalia ; Paterniti, Irene ; Ahmad, Akbar ; Campolo, Michela ; Esposito, Emanuela ; Cuzzocrea, Salvatore. / Effects of palmitoylethanolamide and luteolin in an animal model of anxiety/depression. In: CNS and Neurological Disorders - Drug Targets. 2013 ; Vol. 12, No. 7. pp. 989-1001.
@article{773205d6f6bf4fdab914145521e641f5,
title = "Effects of palmitoylethanolamide and luteolin in an animal model of anxiety/depression",
abstract = "The antidepressant effect of a compound formed by co-ultramicronized palmitoylethanolamide (PEA) and luteolin (PEA+luteolin) was investigated in a mouse model of anxiety/depressive-like behavior. 129Sv/Ev mice were subjected to 6 weeks of corticosterone administration, and then behavior, neurogenesis, neuroplasticity, neurotrophic and apoptotic proteins expression were evaluated. The effect of PEA+luteolin compound treatment (1mg/kg, i.p.), on depression-like behaviour was assessed using different paradigms such as open field, novelty suppressed feeding, forced swim test and elevated plus maze. In particular in the open field, novelty suppressed feeding and elevated plus maze the time spent in the open arm was employed as an indicator of anxiety; forced swim test was used to evaluate the antidepressant capacity of PEA+luteolin on immobility time as an indicator of depression. Adult hippocampal neurogenesis and neuroplasticity were evaluated by immunohistochemical techniques; brain-derived neurotrophic factor and apoptotic protein (Bax and Bcl2) expression were studied by immunostaining and Western blot analysis. For the first time we demonstrated that PEA+luteolin compound exerts a significant antidepressant effect a low dose and may be considered as a novel therapeutic strategy in depression.",
keywords = "Antidepressant, Behavior, Depression, Inflammation, Mice, Neurogenesis",
author = "Rosalia Crupi and Irene Paterniti and Akbar Ahmad and Michela Campolo and Emanuela Esposito and Salvatore Cuzzocrea",
year = "2013",
month = "11",
doi = "10.2174/18715273113129990084",
language = "English (US)",
volume = "12",
pages = "989--1001",
journal = "CNS and Neurological Disorders - Drug Targets",
issn = "1871-5273",
publisher = "Bentham Science Publishers B.V.",
number = "7",

}

TY - JOUR

T1 - Effects of palmitoylethanolamide and luteolin in an animal model of anxiety/depression

AU - Crupi, Rosalia

AU - Paterniti, Irene

AU - Ahmad, Akbar

AU - Campolo, Michela

AU - Esposito, Emanuela

AU - Cuzzocrea, Salvatore

PY - 2013/11

Y1 - 2013/11

N2 - The antidepressant effect of a compound formed by co-ultramicronized palmitoylethanolamide (PEA) and luteolin (PEA+luteolin) was investigated in a mouse model of anxiety/depressive-like behavior. 129Sv/Ev mice were subjected to 6 weeks of corticosterone administration, and then behavior, neurogenesis, neuroplasticity, neurotrophic and apoptotic proteins expression were evaluated. The effect of PEA+luteolin compound treatment (1mg/kg, i.p.), on depression-like behaviour was assessed using different paradigms such as open field, novelty suppressed feeding, forced swim test and elevated plus maze. In particular in the open field, novelty suppressed feeding and elevated plus maze the time spent in the open arm was employed as an indicator of anxiety; forced swim test was used to evaluate the antidepressant capacity of PEA+luteolin on immobility time as an indicator of depression. Adult hippocampal neurogenesis and neuroplasticity were evaluated by immunohistochemical techniques; brain-derived neurotrophic factor and apoptotic protein (Bax and Bcl2) expression were studied by immunostaining and Western blot analysis. For the first time we demonstrated that PEA+luteolin compound exerts a significant antidepressant effect a low dose and may be considered as a novel therapeutic strategy in depression.

AB - The antidepressant effect of a compound formed by co-ultramicronized palmitoylethanolamide (PEA) and luteolin (PEA+luteolin) was investigated in a mouse model of anxiety/depressive-like behavior. 129Sv/Ev mice were subjected to 6 weeks of corticosterone administration, and then behavior, neurogenesis, neuroplasticity, neurotrophic and apoptotic proteins expression were evaluated. The effect of PEA+luteolin compound treatment (1mg/kg, i.p.), on depression-like behaviour was assessed using different paradigms such as open field, novelty suppressed feeding, forced swim test and elevated plus maze. In particular in the open field, novelty suppressed feeding and elevated plus maze the time spent in the open arm was employed as an indicator of anxiety; forced swim test was used to evaluate the antidepressant capacity of PEA+luteolin on immobility time as an indicator of depression. Adult hippocampal neurogenesis and neuroplasticity were evaluated by immunohistochemical techniques; brain-derived neurotrophic factor and apoptotic protein (Bax and Bcl2) expression were studied by immunostaining and Western blot analysis. For the first time we demonstrated that PEA+luteolin compound exerts a significant antidepressant effect a low dose and may be considered as a novel therapeutic strategy in depression.

KW - Antidepressant

KW - Behavior

KW - Depression

KW - Inflammation

KW - Mice

KW - Neurogenesis

UR - http://www.scopus.com/inward/record.url?scp=84889047743&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84889047743&partnerID=8YFLogxK

U2 - 10.2174/18715273113129990084

DO - 10.2174/18715273113129990084

M3 - Article

C2 - 23844686

AN - SCOPUS:84889047743

VL - 12

SP - 989

EP - 1001

JO - CNS and Neurological Disorders - Drug Targets

JF - CNS and Neurological Disorders - Drug Targets

SN - 1871-5273

IS - 7

ER -